ANGIODYNAMICS INC ANGO
AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance.
AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility. Initially dedicated to the research and development of products used in interventional radiology, the Company soon became well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320.2M | $292.5M | $303.9M | $338.8M | $316.2M | $291.0M | $264.2M | $270.6M | $261.7M | $269.8M |
| Cost of revenue | $145.3M | $134.8M | $149.2M | $164.5M | $150.5M | $134.2M | $113.9M | $114.6M | $117.8M | $125.8M |
| Gross profit | $174.9M | $157.7M | $154.7M | $174.2M | $165.7M | $156.8M | $150.3M | $156.0M | $143.9M | $143.9M |
| R&D | $29.4M | $26.2M | $31.5M | $29.9M | $30.7M | $36.4M | $29.7M | $28.3M | $24.3M | $24.1M |
| SG&A | $43.7M | $42.1M | $41.2M | $40.0M | $38.5M | $35.9M | $37.9M | $34.9M | $31.0M | $31.1M |
| Total operating expenses | $214.8M | $197.7M | $401.6M | $225.4M | $194.2M | $192.1M | $317.4M | $165.4M | $158.0M | $155.1M |
| Operating income | -$39.9M | -$40.0M | -$192.4M | -$51.2M | -$28.5M | -$35.3M | -$167.1M | -$9.4M | -$14.2M | -$11.2M |
| Interest expense | — | — | $1.6M | $2.7M | $688.0K | $861.0K | $907.0K | $5.1M | $3.1M | $2.8M |
| Pre-tax income | -$36.3M | -$34.0M | -$191.6M | -$54.4M | -$29.9M | -$36.1M | -$168.1M | -$14.7M | -$17.3M | -$14.3M |
| Income tax | $442.0K | $39.0K | $7.3M | $2.0M | $3.4M | $4.5M | $1.3M | $3.6M | $11.0M | $7.2M |
| Net income | -$36.7M | -$34.0M | -$184.3M | -$52.4M | -$26.5M | -$31.5M | -$166.8M | $61.3M | $16.3M | $5.0M |
| EPS, basic | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 | -4.39 | 1.64 | 0.44 | 0.14 |
| EPS, diluted | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 | -4.39 | 1.64 | 0.44 | 0.14 |
| Shares, diluted (wtd. avg.) | $41.5M | $40.9M | $40.2M | $39.5M | $39.0M | $38.3M | $38.0M | $37.5M | $37.1M | $36.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $53.9M | $55.9M | $76.1M | $44.6M | $28.8M | $48.2M | $54.4M | $227.6M | $74.1M | $47.5M |
| Short-term investments | — | — | — | — | — | — | — | $0 | $1.3M | $1.2M |
| Receivables | $48.3M | $42.9M | $43.6M | $52.8M | $52.3M | $35.4M | $31.3M | $43.6M | $39.4M | $44.5M |
| Inventory | $52.4M | $62.0M | $60.6M | $55.3M | $51.4M | $48.6M | $59.9M | $40.1M | $39.3M | $54.5M |
| Total current assets | $163.4M | $168.3M | $193.3M | $163.5M | $143.3M | $140.9M | $152.9M | $315.3M | $168.0M | $153.9M |
| Property, plant and equipment | $27.1M | $32.3M | $35.7M | $44.4M | $45.0M | $37.1M | $28.3M | $24.3M | $25.7M | $45.2M |
| Goodwill | — | — | $0 | $159.2M | $201.1M | $201.3M | $200.5M | $347.7M | $361.3M | $361.3M |
| Other intangibles | $67.2M | $69.1M | $77.4M | $111.1M | $152.4M | $169.0M | $197.1M | $145.4M | $112.5M | $145.7M |
| Total assets | $267.2M | $280.1M | $317.7M | $532.6M | $552.8M | $561.4M | $594.2M | $836.4M | $705.5M | $708.0M |
| Accounts payable | $31.5M | $33.3M | $37.8M | $40.4M | $28.0M | $19.6M | $19.1M | $22.8M | $15.8M | $18.1M |
| Short-term debt | — | — | — | — | — | — | $0 | $7.5M | $5.0M | $5.0M |
| Total current liabilities | $74.7M | $76.2M | $91.2M | $83.8M | $74.3M | $57.6M | $51.4M | $73.3M | $57.3M | $71.5M |
| Long-term debt | — | — | $0 | $49.8M | $25.0M | — | — | $124.4M | $86.6M | $91.3M |
| Total liabilities | $96.3M | $97.2M | $112.1M | $154.3M | $128.3M | $122.0M | $139.3M | $221.6M | $162.9M | $192.9M |
| Retained earnings | -$465.9M | -$429.2M | -$395.2M | -$210.9M | -$158.4M | -$131.9M | -$100.3M | $66.5M | $5.1M | -$11.0M |
| Total equity | $170.8M | $183.0M | $205.6M | $378.3M | $424.5M | $439.5M | $454.9M | $614.8M | $542.6M | $515.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.1M | -$10.1M | -$28.2M | $78.0K | -$7.2M | $24.1M | -$14.6M | $37.4M | $41.3M | $55.7M |
| Depreciation and amortisation | $10.5M | $13.5M | $14.7M | $11.9M | $7.6M | $5.7M | $3.3M | $3.1M | $3.4M | $4.8M |
| Stock-based compensation | $14.0M | $9.8M | $10.5M | $11.2M | $10.7M | $8.6M | $7.6M | $9.2M | $7.9M | $6.2M |
| Capital expenditure | $2.6M | $4.5M | $2.5M | $3.8M | $4.3M | $5.2M | $7.2M | $3.1M | $2.4M | $3.0M |
| Investing cash flow | -$5.9M | -$10.2M | $123.7M | -$9.7M | -$19.3M | -$13.7M | -$63.3M | $82.6M | -$3.7M | -$2.6M |
| Financing cash flow | $564.0K | -$255.0K | -$64.2M | $25.4M | $7.7M | -$17.0M | -$95.2M | $33.9M | -$11.6M | -$38.0M |
| Buybacks | $0 | $1.7M | $0 | $0 | — | — | — | $0 | $0 | $13.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-048138.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |